SAN DIEGO, Calif., December 3, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced its participation in the American Epilepsy Society (AES) 2025 Annual Meeting.
The AES meeting brings together clinicians, researchers, and patient advocates dedicated to improving outcomes in epilepsy and related disorders. Bloom’s team engaged with key opinion leaders to discuss advances in gut-brain axis research and therapeutic opportunities in rare epilepsies.
Bloom’s lead program, BL-001, is being developed with potential applications in neurological disorders including Dravet syndrome.
“We are committed to working alongside the epilepsy community to advance innovative treatment options,” said Dr. Reyes.
About Bloom Science, Inc.
Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.